CHMP adopts positive opinion recommending approval of new and expanded indications for SPEVIGO®

  • The CHMP positive opinion is based on the EFFISAYIL® 2 trial, which showed that no flares were observed after week 4 of SPEVIGO® administered subcutaneously. During the 48-week trial, an 84% reduction of the risk of GPP flares was observed.
  • GPP is a rare, chronic, heterogenous neutrophilic inflammatory disease associated with skin flares and systemic symptoms, such as fever, pain, and fatigue.
  • SPEVIGO® is currently approved in 51 countries for treatment of GPP flares, and the CHMP opinion follows similar approvals for expanded and new indications in the US and China.

Boehringer Ingelheim today announced that the European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended approval of a new indication of SPEVIGO® (spesolimab) injection for the prevention of generalized pustular psoriasis (GPP) flares in adults and adolescents from 12 years of age; and extension of the approved indication for SPEVIGO® (spesolimab) infusion for the treatment of generalized pustular psoriasis (GPP) flares in adults and adolescents from 12 years of age as monotherapy. SPEVIGO® is a novel, humanized selective IgG1 antibody that binds to interleukin-36 receptor (IL-36R), a key part of a signaling pathway within the immune system shown to be involved in the cause of GPP.

The regulatory authorities’ decisions are based on the positive results of the EFFISAYIL® 2 trial, a 48-week clinical trial that showed that SPEVIGO® significantly reduced the risk of GPP flares by 84%, compared with placebo. In the trial with 123 patients, no flares were observed after week 4 of SPEVIGO® subcutaneous treatment in the high-dose group (n=30). The EFFISAYIL® 2 trial showed a similar incidence of patients with adverse events across spesolimab and placebo treatment arms.

“GPP presents a significant diagnostic challenge for healthcare professionals as it is a highly variable rare disease that is experienced differently by everyone who has it, and it has suffered from a historic lack of treatment options,” said Dr Peter van der Kerkhof, Professor and previous Chairman of the Department of Dermatology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands. “Spesolimab’s recent approvals, combined with the CHMP recommendation provides us with the potential for continuous treatment, addressing a significant unmet need.”

Distinct from plaque psoriasis, GPP is a rare, chronic, heterogenous, inflammatory neutrophilic disease associated with painful skin manifestations and systemic symptoms, such as fever, pain, and fatigue. GPP varies widely between individuals living with the condition, with symptoms presenting both above and below the skin. Uncontrolled GPP may require emergency care and can lead to life-threatening complications, such as multi-organ failure and sepsis. GPP’s unpredictable nature can potentially have significant long-term impacts on quality of life for people living with it and leads to fear and anxiety over the disease course.

“The CHMP’s positive opinion on SPEVIGO®, alongside approvals in China and the US, signals a strong shift in treatment, offering people living with the disease the potential for significant improvement of their condition and a better quality of life,” said Carinne Brouillon, Member of the Board of Managing Directors and Head of Human Pharma at Boehringer Ingelheim. “The potential to prevent GPP flare-ups means a possibility to gain back control over how people affected by the disease live their lives.”

'GPP goes way beyond the skin, it's a relentless and unpredictable disease that can impact every aspect of a person's life,” said Frida Dunger, Executive Director, IFPA (International Federation of Psoriasis Associations). “I want a world where every person with GPP is diagnosed quickly and receives the treatment they need, and this is their right. There is much more to do, but I believe with all stakeholders working together we are headed in the right direction.”

About SPEVIGO®
SPEVIGO® is a novel, humanized, selective antibody that specifically blocks the activation of the IL-36R, a signaling pathway within the immune system shown to be involved in the pathogenesis of several autoinflammatory diseases, including GPP. It is the first targeted therapy for the treatment of GPP and has been evaluated in the largest clinical program specifically for the treatment of patients with GPP.

About generalized pustular psoriasis (GPP)
GPP is a chronic, heterogenous, neutrophilic inflammatory disease associated with skin and systemic symptoms that is distinct from plaque psoriasis. GPP is recognized as a separate clinical entity from other forms of psoriasis, with the IL-36 pathway being a key driver of GPP and triggering response to treatment. Prevalence of GPP varies considerably across geographical regions, ranging from 1.76 to 124 patients per million persons. GPP can become life-threatening (mortality rates ranging from 2% to 16%) due to severe complications, such as multisystem organ failure and sepsis requiring urgent hospital care; many GPP patients also suffer from various comorbidities, which contribute to the ongoing burden for the patient and healthcare systems. GPP symptoms appear unpredictable and present on a continuum, which greatly impacts a patient’s quality of life, and may cause fear and anxiety over the disease course, as well as long-term impacts on quality of life related to work/school, emotional health, social activities, and finances.

About the EFFISAYIL® clinical trial program
The EFFISAYIL® clinical trial program evaluated the largest and broadest population of GPP patients in trials of a therapy specifically targeting the IL-36 pathway for GPP.

  • EFFISAYIL® 1: A Phase II study that demonstrated treatment with a single intravenous dose of spesolimab significantly improved signs and symptoms of GPP in patients experiencing a flare, including rapid pustular and skin clearance. These results supported the approval of spesolimab as the first specific treatment for GPP flares in adults in major markets.
  • EFFISAYIL® 2: A Phase IIb study that showed subcutaneous spesolimab significantly reduced the risk of GPP flares by 84% over 48 weeks compared to placebo. In the trial with 123 patients, no flares were observed after week 4 of spesolimab SC treatment in the high-dose group (n=30).
  • EFFISAYIL® ON: An open-label extension study to evaluate the long-term safety and efficacy of spesolimab in patients with GPP who have completed previous spesolimab trials.
  • EFFISAYIL® REP (ongoing): An open-label, single-arm, Phase IIIb/IV trial to evaluate the efficacy, safety, and the impact of immunogenicity in the treatment of patients with GPP presenting with a recurrent flare following their initial GPP flare treatment with spesolimab IV.

About Boehringer Ingelheim
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Learn more at https://www.boehringer-ingelheim.com/.


CHMP adopts positive opinion recommending approval of new and expanded indications for SPEVIGO®

THỦ THUẬT HAY

Hướng dẫn kích hoạt bảo mật 2 lớp cho Apple ID

Xác thực 2 lớp là tầng bảo mật bổ sung được thiết kế để ngăn chặn truy cập trái phép vào tài khoản của bạn, đồng thời bảo vệ ảnh, tài liệu và các dữ liệu khác được lưu với Apple.

Cách vô hiệu hóa chế độ khóa máy khi nhập sai mật khẩu iPhone

Mặc định iPhone sẽ chỉ cho phép người dùng nhập sai mật khẩu máy một số lần quy định. Nếu nhập không đúng thì thiết bị sẽ bị vô hiệu hóa hoàn toàn, thậm chí xóa hết dữ liệu nếu bật tính năng Erase All Data. Để mở máy

Cách tắt Wi-Fi khi kết nối Ethernet trong Windows 10

Việc sử dụng Wi-Fi trên các thiết bị di động và máy tính cực kì tiện lợi nhưng mặt trái của nó là rất ngốn pin. Do đó, bất cứ khi nào bạn có thể sử dụng mạng Ethernet (mạng có dây) thì bạn nên tận dụng triệt để. Tuy

Hướng dẫn tìm và đổi các mật khẩu yếu dễ dàng trên iOS 12

Tính năng tự động điền mật khẩu trên iPhone đã xuất hiện được khoảng một thời gian, nhưng với iOS 12 tính năng này lại càng hữu dụng bằng cách đề xuất mật khẩu mạnh khi tạo tài khoản trong Safari hoặc trong ứng dụng.

Hướng dẫn gỡ bỏ các ứng dụng mặc định Windows 10

Trước khi bắt đầu, bạn nên lưu ý rằng nếu không thực sự cần thiết thì bạn không nên gỡ các ứng dụng có sẵn. Những ứng dụng này chỉ chiếm một lượng nhỏ không gian trên thiết bị, do đó tốt nhất là bạn nên “bơ” chúng nếu

ĐÁNH GIÁ NHANH

So sánh thời lượng pin iPhone 13 Pro Max và Galaxy S21 Ultra: Chiến thắng thuộc về ai?

Thay vì đọ cấu hình, một test so sánh thời lượng pin iPhone 13 Pro Max và Galaxy S21 Ultra đã được thực hiện. Với dung lượng pin lớn hơn liệu Galaxy S21 Ultra có chiến đánh bại được đối iPhone 13 Pro Max hay không? Hãy

Trên tay iMac Pro: Cấu hình siêu mạnh trong thân máy mỏng nhẹ, ít tốn điện

Bằng cách sử dụng CPU được Intel tùy biến riêng, SSD được chế tạo độc quyền cho iMac Pro hay các giải pháp nhà làm như con chip bảo mật T2, Apple đã có thể 'nhét' được một cấu hình siêu mạnh vào một thân máy mỏng nhẹ,

Trên tay và đánh giá nhanh về bộ ba viên pin dự phòng cao cấp và mới nhất của Energea

Trong loạt sản phẩm mới này của mình, nhà sản xuất tới từ Singapore dường như đã đặt trải nghiệm cũng như sự cao cấp lên hàng đầu. Bạn có thể nhìn thấy được ưu nhược điểm của từng sản phẩm một và dễ dàng để chọn lựa